Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides

Brooke A. Anderson(Ionis Pharmaceuticals (United States)), Punit P. Seth(Ionis Pharmaceuticals (United States)), William J. Drury(Ionis Pharmaceuticals (United States)), Michael Fazio(Ionis Pharmaceuticals (United States)), Eli Scandalis(Ionis Pharmaceuticals (United States)), Sebastien A. Burel(Ionis Pharmaceuticals (United States)), Xue‐hai Liang(Arisan Therapeutics (United States)), Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Timothy A. Vickers(Ionis Pharmaceuticals (United States)), Audrey Low(Ionis Pharmaceuticals (United States)), Michael T. Migawa(Ionis Pharmaceuticals (United States)), Graeme C. Freestone(Ionis Pharmaceuticals (United States)), Andrés Berdeja(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Stanley Foundation), Cheryl L De-Hoyos(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States))
Nucleic Acids Research
August 19, 2021
10.1093/nar/gkab718
Cited by 129

Related Papers

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
|The Lancet|2010|905
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary<i>N</i>-acetyl galactosamine improves potency 10-fold in mice
|Nucleic Acids Research|2014|594
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
|Nucleic Acids Research|2006|461
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant.
|Molecular and Cellular Biology|1994|354
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
|Journal of Lipid Research|2007|291